With programs using both somatic cells and iPSCs, and an NK platform for oncology in the works, Japan's Healios aims to be a leader in regenerative medicine

blonca9
Nov 17, 2024
1 min read

CEO Hardy Kagimoto describes the company's programs, including how Multistem could soon be conditionally approved in Japan and is scheduled to enter a global phase 3 in ARDS. Plus, stroke, RPE tear AMD, and NK cells for solid tumors.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

With programs using both somatic cells and iPSCs, and an NK platform for oncology in the works, Japan's Healios aims to be a leader in regenerative medicine

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight